Friday, January 08, 2021

#CleanEnergy #Stocks in the News (TSX-V: $DEFN.V) (OTCQB: $DFMTF) - JINKOSOLAR (NYSE: $JKS), DEFENSE METALS, BYD - DEMAND BOOM LEADS TO CATASTROPHE!; @DefenseMetals

#CleanEnergy #Stocks in the News (TSX-V: $DEFN.V) (OTCQB: $DFMTF) - JINKOSOLAR (NYSE: $JKS), DEFENSE METALS, BYD - DEMAND BOOM LEADS TO CATASTROPHE!; @DefenseMetals 

 

Vancouver, British Columbia January 8, 2021 – Investorideas.com Newswire –Media alert for Defense Metals Corp. (TSX-V: DEFN / OTCQB: DFMTF / FSE: 35D).The company was featured in the following  article : JINKOSOLAR, DEFENSE METALS, BYD - DEMAND BOOM LEADS TO CATASTROPHE!

 

Read this news, featuring DEFN in full at https://www.investorideas.com/news/2021/mining/01081Defense-Metals-Demand-Boom.asp

 

Full article and Original source

https://news.financial/comments/jinkosolar-defense-metals-byd-demand-boom-leads-to-catastrophe  


Excerpt:

The sales figures for all major electric car manufacturers for the full year 2020 are on the table. 100% more e-cars were sold compared to the same period last year. But even more significant for the future is that vehicles with electric motors have overtaken pure combustion engines in new deliveries. The disruptive replacement is in full swing. However, shortages are emerging in the raw materials needed for the production of batteries and motors.

 

SHORTAGE OF RAW MATERIALS

In addition to lithium, which is needed for the production of batteries, there is also an enormous surplus of demand for other raw materials. This demand will become much more acute in the coming years. Permanent magnets for electric motors are produced based on rare earth metals. In ten years, the experts at Adamas Intelligence predict that demand for rare earth oxides for use in magnets will rise from USD 2.98 billion to USD 15.65 billion. The analysts at Adamas Intelligence see by far the most significant demand primarily for rare earth magnets such as neodymium, praseodymium, dysprosium and terbium. Even more severe is the short-term view of three to five years. The demand for rare earths is growing so enormously that the already insufficient production capacities will not be enough by far. It is a must to make significant investments in the mining industry to saturate demand to some extent.

 

CHINA'S SUPERIORITY

The People's Republic of China has a virtual monopoly with 80% of rare earth metals production. Politicians are desperately looking for alternatives in Europe or North America. Defense Metals, a mineral explorer, is at the top of the list. Founded in 2016, the Company focuses on acquiring mineral deposits that contain metals and elements used in the production of renewable energy technologies, such as rare earth magnets. Research is underway at the Wicheeda project in the province of British Columbia. The Company says mineral resources are 4.9 million tons at an average grade of 3.02% LREO (light rare earth metals) and inferred mineral resources of 12.1 million tons at an average grade of 2.90% LREO.

 

CASH BOOST AND THE SHARE PRICE JUMPS

At the end of December, the Company announced that it would receive approximately CAD 632,000 from the exercise of 3.157 million warrants. These funds will be used to strengthen working capital and, in particular, to complete the preliminary economic assessment (PEA) of the project. The stock market is slowly recognizing the extreme demand for rare earth metals. Defense Metals shares have almost doubled to CAD 0.30 in the past four weeks and are close to their 2018 all-time high, but the stock market value is currently just under EUR 10 million. Given the further increase in demand due to the electric car boom, there is still significant room for improvement.

 

"BUILD YOUR DREAMS" CONTINUES

The importance of the procurement of lithium and rare earth metals is shown by the delivery figures for BYD for December. The Chinese Company sold a total of 56,322 vehicles in the last month of fiscal year 2020. In the previous month, the figure was 53,943 units. Compared to December 2019, this represents a significant increase of over 13,000 units. Crucially, however, the report showed that for the first time in the Company's history, more NEVs were sold than internal combustion vehicles.

 

LESS GROWTH THAN COMPETITORS

Indeed, BYD is still well ahead of competitors such as NIO (NYSE: NIO) or Xpeng (NYSE: XPEV)  in terms of delivery figures. However, sales of electric cars were lower in percentage terms than those of its main Chinese competitors compared to the previous month. Although the share started the day almost 3% down, it managed to get back into the black over the course of the day.

 

NEW RECORD

The Chinese photovoltaic producer JinkoSolar was able to break its world record. An efficiency of 24.9% was achieved for a large, n-type, TOPCon, monocrystalline solar cell. According to the Company, the monocrystalline solar cell was manufactured on a high-quality, low-defect CZ mono-Si substrate. Earlier this year, when the cell still had an efficiency of 24.2%, JinkoSolar (NYSE: JKS) said the cell was based on the HOT design and featured tunnel oxide passivated contact technology.


Author
STEFAN FEULNER

 

About Defense Metals Corp. https://defensemetals.com/

Defense Metals Corp. is a mineral exploration company focused on the acquisition of mineral deposits containing metals and elements commonly used in the electric power market, military, national security and the production of “GREEN” energy technologies, such as, high strength alloys and rare earth magnets. Defense Metals has an option to acquire 100% of the 1,708 hectare Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

 

For further information, please contact:

Todd Hanas, Bluesky Corporate Communications Ltd.

Vice President, Investor Relations

Tel: (778) 994 8072

Email: todd@blueskycorp.ca

 

Forward Looking Information

This news release contains “forwardlooking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to finding partnerships, securing potential offtake agreements, and other business opportunities, the technical, financial and business prospects of the Company, its project and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including those filed under the Company’s profile on SEDAR at www.sedar.com. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather conditions, failure to maintain all necessary government permits, approvals and authorizations, failure to maintain community acceptance (including First Nations), decrease in the price of rare earth elements, the impact of Covid-19 or other viruses and diseases on the Company’s ability to operate increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forwardlooking statements or forwardlooking information, except as required by law.

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: this news release featuring Defense Metals Corp. is a paid for service on Investorideas.com ($750) more disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

RenewableEnergyStocks.com: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our Renewable Energy Stocks Directory

Get News Alerts on Renewable Energy Stocks

Buy a renewable energy guest post on Investorideas.com

 


MiningSectorStocks.com - investing ideas in mining stocks

Like Mining Stocks? View our Mining Stocks Directory  Get News Alerts on Mining Stocks

 

 

 

 

 

 

 

Thursday, January 07, 2021

#AIEye #Podcast 505: GBT Tokenize (OTCPINK: $GTCH) Researching #AI Detection System and Datametrex (TSXV: $DM.V) to Acquire 100% of Concierge Medical Consultants; #artificialintelligence

#AIEye #Podcast 505: GBT Tokenize (OTCPINK: $GTCH) Researching #AI Detection System and Datametrex (TSXV: $DM.V) to Acquire 100% of Concierge Medical Consultants; #artificialintelligence

 

Global Intelligent Drug Discovery Market to Reach $3.71 Billion by 2027

 


Point Roberts WA, Vancouver BC – January 7, 2021  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence  –  featuring technology company GBT Technologies Inc. (OTCPINK:GTCH).

 

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2021/010721-AI-Eye.mp3

 

Read this in full at https://www.investorideas.com/news/2021/artificial-intelligence/01071GTCH-Datametrex.asp

 

Hear the Ai Eye on Spotify  

 

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

 

Stocks discussed: (OTCPINK:GTCH) (TSXV:DM)

 

GBT Tokenize Corp, the joint venture of GBT Technologies Inc. (OTC PINK:GTCH), is continuing research on an AI system to detect and open clogs within arteries based on its proprietary radio technology, which has an internal code name of "Hermes". Danny Rittman, GBT’s CTO, explained:

 

"Our AI technology can be implemented in a wide variety of applications to control mechanical, optical and electrical systems, analyzing arterial data and making decisions in real time. We are commencing research - code name Hermes, to use our AI capabilities to search, identify and remove plaque within arteries and blood vessels. In this project, we are researching the ability to use GBT Tokenize's AI technology to control a mini-probe unit that will be inserted into a human body through a main artery. If our research is positively concluded, we believe that this type of system can be a breakthrough within the cardiovascular domain, offering less invasive treatments and introducing a new method to save lives. Artificial Intelligence technology encapsulates the future health care and we're investing vast efforts to utilize our experience and knowledge in this domain."

 

Datametrex AI Limited (TSXV:DM) has entered into a binding Letter of Intent to acquire 100 percent of Concierge Medical Consultants Inc., described in the press release as “an arm's length private telehealth and medical concierge services company.” Datametrex CEO Marshall Gunter said:

 

"The significance of the acquisition of this medical business cannot be understated. The demand for telehealth and concierge medical service is expected to continue to strengthen as the market for remote healthcare grows. We look forward to working with Dr. Sharif (founder and CEO of Concierge Medical Consultants) and his medical team to grow this business under Datametrex."

 

 

Global Intelligent Drug Discovery Market to Reach $3.71 Billion by 2027

 

A report published by Emergen Research finds that the global Intelligent Drug Discovery market will grow from $258.9 million in 2019 to $3.71 billion by 2027 with a compound annual growth rate (CAGR) of 39.4 percent in the forecast period. An excerpt from the report synopsis outlines the role of AI in the market:

 

 

Artificial intelligence is commonly used in the development of novel drugs. The market manufacturers are investing in partnerships and collaborations to drive the demand for technology. It reduces time as well as the overall cost of the drug development procedure, which makes it attractive among pharmaceutical companies. The dearth of a skilled professional and lack of data sets are hindering its growth. Furthermore, increasing awareness of the integration of AI in the healthcare industry will offer growth opportunities to the market.

 

Sam Mowers, Investorideas.com

 

Read and hear other editions of the AI  Eye

 

For a list of artificial intelligence stocks on Investorideas.com visit here

Investors can trade these stocks and other ideas on our site using our  list of top stock trading apps including Robinhood , Acorn, Stash  and others.

About GBT Technologies Inc.

GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development-stage company which considers itself a native IoT creator, developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology platforms.  GBT has a portfolio of Intellectual Property that, when commercialized, will include smart microchips, mobile and security applications and protocols, and supporting cloud software.  GBT’s system envisions the creation of a global mesh network.  The core of the system will be its advanced microchip technology that can be installed in any mobile or fixed device worldwide. GBT envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing and enhanced mobile features as an alternative to traditional carrier services.

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com 

Disclosure: GTCH is a paid monthly ai stock on investor ideas 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 




Get more Technology stock investor ideas - news, articles, podcasts and stock directories

#CryptoCorner #Podcast Episode 503: #Stocks discussed: (NasdaqGS:$EQOS) (TSX: $HUT.TO) (OTCQB: $INTV)

#CryptoCorner #Podcast Episode 503: #Stocks discussed: (NasdaqGS:$EQOS) (TSX: $HUT.TO) (OTCQB: $INTV)

 

#Bitcoin Scores Another New ATH at Over $38K, ETH and XRP Rally, Diginex’s EQUOS Launches BTC Perpetual Futures Contract, Hut 8 Announces Bitcoin Yield Account, and Argo #Blockchain Reports Operational Update for December 2020

 

 


Point Roberts, WA, Delta BC January 7, 2021 -  Investorideas.com, a leader in crypto and blockchain investing news brings you today’s edition of the Crypto Corner podcast and commentary on what’s driving cryptocurrency stocks and the crypto market.  Today’s podcast was sponsored by Integrated Ventures (OTCQB: INTV) , a company focused on acquiring, launching and operating assets in the cryptocurrency sector.

 

Listen to today’s Crypto Corner Podcast:  

https://www.investorideas.com/Audio/Podcasts/2021/010721-CryptoMarket.mp3

 

Read this in full at https://www.investorideas.com/news/2021/crypto-corner/01071EQOS-HUT-INTV.asp

 

Get the Crypto Corner Podcast on iTunes

 

Get the Crypto corner on Spotify

 

Stocks discussed: (NasdaqGS:EQOS) (TSX:HUT) (LSE:ARB)

 

Bitcoin (BTC) has done it again, registering another all-time high over the past day, this time peaking at about $38,460, and trading for around $38,320 at press time, according to data from CoinMarketCap. For perspective, this is nearly $4,000 higher than it was trading for at the time of yesterday’s Crypto Corner, and puts Bitcoin up about 30 percent for the year, so far. Ether (ETH) is also enjoying a surge, having grown roughly 7 percent in the past 24 hours, and 66 percent in the past week, with a current trading price of about $1,220. Perhaps most notable, XRP is up 43 percent since yesterday, at press time, in spite of Ripple’s being sued by the SEC and delistings from major exchanges in the past weeks.

 

EQUOS, the crypto exchange of digital assets financial services company Diginex Limited (NasdaqGS:EQOS), has launched its Bitcoin (BTC) Perpetual Futures Contract. Diginex CEO Richard Byworth said:

 

"Our goal is to develop products with functionality that will facilitate wider institutional and professional trader adoption of cryptoassets. This is just the first in a product suite that will offer investors more dynamic hedging tools, fairer liquidation, a platform that is not trading against its users and reputational protection for investors seeking a KYC/AML compliant ecosystem."

 

Hut 8 Mining Corp. (TSX:HUT) has announced the opening of a Bitcoin Yield Account in partnership with Genesis Global Capital. According to the press release, this account “will enable Hut 8 to earn at a 4 per cent rate of return on its BTC Holdings.” Jaime Leverton, CEO of Hut 8, explained:

 

"At Hut 8, our strategy is focused on creating incremental value. We are excited to be partnering with Genesis to manage our digital assets, allowing us to yield Fiat currency from the significant BTC on our balance sheet, minimize Hut 8's Fiat expenses and subsequently expand our ability to hold Bitcoin rather than sell. Our current momentum and trajectory are just the start of what's to come in 2021 for Hut 8 and its investors."

 

UK-based crypto miner Argo Blockchain (LSE:ARB) has reported an operational update for December, 2020. During that month, the company mined 96 Bitcoin or Bitcoin Equivalent (BTC) – down from 115 Bitcoin Equivalent in November – bringing the total amount of BTC mined year-to-date to 2,465 BTC. Argo’s mining revenue in December reached £1.63 million ($2.21 million USD). The company’s CEO, Peter Wall, said:

 

"I am delighted that Argo has delivered strong mining revenue for December and at such a healthy margin. The Bitcoin market has entered 2021 on a roll, and we are very optimistic this year will continue to see an increasing mainstream adoption of cryptocurrency. We look to the future with much optimism."

 

Sam Mowers, Investorideas

 

For investors following the sector Investor Ideas has a comprehensive Bitcoin, Blockchain and Digital Currency Stocks Directory

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood , Acorn, Stash  and others.

Crypto Corner Podcast sponsor


Integrated Ventures (OTCQB: INTV) is focused on acquiring, launching and operating assets in the cryptocurrency sector. 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Crypto Corner is part of the Investor Ideas Membership content

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

 

Visit the Podcast page at Investorideas.com: https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Disclosure : INTV is a featured monthly crypto stock on Investorideas.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Cryptocurrency Disclaimer

Investorideas.com news content is not meant to be a solicitation to buy or sell cryptocurrencies and Investorideas.com does not directly sell cryptocurrencies; but acts as a news and research resource for interested investors following the blockchain sector.

Copyright and ownership: Crypto Corner is an Investorideas.com content brand

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800-665-0411

 

 



Get more Bitcoin and Blockchain Investor ideas  – news, articles, podcasts and stock directories 

#Medtech #Stocks in the News; Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles; @Sigyn_inc

#Medtech #Stocks in the News; Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles; @Sigyn_inc

 

SAN DIEGO CA, January 7, 2021 -- (Investorideas.com Newswire) Medical Therapeutic technology stock news - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY, a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream. 

 

Read this news, featuring SIGY in full at https://www.investorideas.com/news/2021/biotech/01071Sigyn-Inflammatory-CytoVesicles.asp

 

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death.  The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide.  Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

 

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions.  Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm.   CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves. 

 

In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma.  After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%.  Previously published studies have validated liposomes as a model for the isolation of  extracellular vesicles from blood based on the similarity of their size and structural characteristics.

 

“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”

 

Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies. 

 

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), is a paid for service on Investorideas.com . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com lease read Investorideas.com privacy policy https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks